191 related articles for article (PubMed ID: 33789622)
1. PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma.
Kim SK; Kim JH; Kim SH; Lee YH; Han JW; Baek W; Woo HY; Jeon MK; Kim HS
BMC Cancer; 2021 Mar; 21(1):336. PubMed ID: 33789622
[TBL] [Abstract][Full Text] [Related]
2. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.
Oh CR; Hong JY; Kim JH; Lee JS; Kim HS; Kim TW; Ahn JH; Kim JE
Target Oncol; 2020 Aug; 15(4):485-493. PubMed ID: 32607656
[TBL] [Abstract][Full Text] [Related]
3. Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.
Benson C; Ray-Coquard I; Sleijfer S; Litière S; Blay JY; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla S; Gil T; Piperno-Neumann S; Marréaud S; Dewji MR; van der Graaf WTA
Gynecol Oncol; 2016 Jul; 142(1):89-94. PubMed ID: 27012429
[TBL] [Abstract][Full Text] [Related]
4. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
Kasper B; Sleijfer S; Litière S; Marreaud S; Verweij J; Hodge RA; Bauer S; Kerst JM; van der Graaf WTA
Ann Oncol; 2014 Mar; 25(3):719-724. PubMed ID: 24504442
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response.
Hong JY; Cho HJ; Yun KH; Lee YH; Kim SH; Baek W; Kim SK; Lee Y; Choi YL; Kwon M; Kim HS; Lee J
Cancer Res Treat; 2023 Apr; 55(2):671-683. PubMed ID: 36164943
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
[TBL] [Abstract][Full Text] [Related]
7. Pazopanib in metastatic soft tissue sarcomas: Testing the waters in developing world.
Bajpai J; Mullapally SK; Kapoor A; Ghosh J; Rekhi B
Indian J Cancer; 2021; 58(3):365-370. PubMed ID: 33753596
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib in the treatment of soft tissue sarcoma.
Schöffski P
Expert Rev Anticancer Ther; 2012 Jun; 12(6):711-23. PubMed ID: 22716487
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
Kollár A; Jones RL; Stacchiotti S; Gelderblom H; Guida M; Grignani G; Steeghs N; Safwat A; Katz D; Duffaud F; Sleijfer S; van der Graaf WT; Touati N; Litière S; Marreaud S; Gronchi A; Kasper B
Acta Oncol; 2017 Jan; 56(1):88-92. PubMed ID: 27838944
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib: in advanced soft tissue sarcoma.
Deeks ED
Drugs; 2012 Nov; 72(16):2129-40. PubMed ID: 23072642
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
Sleijfer S; Ray-Coquard I; Papai Z; Le Cesne A; Scurr M; Schöffski P; Collin F; Pandite L; Marreaud S; De Brauwer A; van Glabbeke M; Verweij J; Blay JY
J Clin Oncol; 2009 Jul; 27(19):3126-32. PubMed ID: 19451427
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib in sarcomas: expanding the PALETTE.
Wilky BA; Meyer CF; Trent JC
Curr Opin Oncol; 2013 Jul; 25(4):373-8. PubMed ID: 23666473
[TBL] [Abstract][Full Text] [Related]
13. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma.
Ranieri G; Mammì M; Donato Di Paola E; Russo E; Gallelli L; Citraro R; Gadaleta CD; Marech I; Ammendola M; De Sarro G
Crit Rev Oncol Hematol; 2014 Feb; 89(2):322-9. PubMed ID: 24041629
[TBL] [Abstract][Full Text] [Related]
14. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.
Duffaud F; Sleijfer S; Litière S; Ray-Coquard I; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla SP; Dewji R; Marreaud S; Verweij J; van der Graaf WT
Eur J Cancer; 2015 Nov; 51(17):2615-23. PubMed ID: 26321011
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy.
Hirbe AC; Eulo V; Moon CI; Luo J; Myles S; Seetharam M; Toeniskoetter J; Kershner T; Haarberg S; Agulnik M; Monga V; Milhem M; Parkes A; Robinson S; Okuno S; Attia S; Van Tine BA
Eur J Cancer; 2020 Sep; 137():1-9. PubMed ID: 32712457
[TBL] [Abstract][Full Text] [Related]
16. Pazopanib, a new therapy for metastatic soft tissue sarcoma.
Verweij J; Sleijfer S
Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study
Gelderblom H; Judson IR; Benson C; Merimsky O; Grignani G; Katz D; Freivogel KW; Stein D; Jobanputra M; Mungul A; Manson SC; Sanfilippo R
Acta Oncol; 2017 Dec; 56(12):1769-1775. PubMed ID: 28723233
[TBL] [Abstract][Full Text] [Related]
18. Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population.
Huang PW; Chou WC; Shen WC; Hung CY; Huang KG; Su YL; Lu CH; Liu CT; Chang YS; Liau CT
Asia Pac J Clin Oncol; 2018 Aug; 14(4):353-360. PubMed ID: 29900662
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study.
Sunar V; Korkmaz V; Akin S; Can Guven D; Arik Z; Ates O; Yilmaz M; Mutlu Meydanli M; Oksuzoglu B
J BUON; 2019; 24(6):2327-2332. PubMed ID: 31983102
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).
Coens C; van der Graaf WT; Blay JY; Chawla SP; Judson I; Sanfilippo R; Manson SC; Hodge RA; Marreaud S; Prins JB; Lugowska I; Litière S; Bottomley A
Cancer; 2015 Sep; 121(17):2933-41. PubMed ID: 26033286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
